Access to Hemlibra
The CHS asks members of the bleeding disorder community for help in getting access to Hemlibra for patients with FVIII inhibitors.
Current delays are unacceptable.
Hemophilia Today
Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.
Research
The Canadian Hemophilia Society (CHS) is pleased to put out a special call for applications for two of its research programs for the 2019-2020 grant period: the CHS/Novo Nordisk Psychosocial Research Program and the CHS – Bayer – ADVANCE Canada Research Program. Deadline: FEBRUARY 8, 2019
Support us
Donations enable us to work to improve lives of people affected by bleeding disorders. Every gift makes a difference. Thank you!
STRATEGIC PLAN | 2016‐2020
CHS 2017 Annual Report
The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.
Q&A about RFPs
We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.
Recombinant factor concentrate charts
Please check out our updated charts listing the recombinant factor concentrates and their description.
